Sarepta Soars on FDA Submission for Duchenne Drug

Updated on

Sarepta Therapeutics Inc. shares soared in late trading after the biotech company announced plans to begin submitting data to U.S. regulators on a drug for the rare disorder Duchenne muscular dystrophy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.